Key result
Atorvastatin lowers triglycerides by ~0.21 mmol/L vs placebo in women with PCOS.
Why the study?
Polycystic ovary syndrome is associated with dyslipidaemia and elevated plasma C-reactive protein that increase cardiovascular disease risk, but the effects of different pharmacological interventions required review.
Do pharmacological interventions improve lipid profiles and reduce C-reactive protein in women with polycystic ovary syndrome?
Population
Women with PCOS across 29 RCTs
Comparison
Different pharmacological interventions vs placebo or other agents
Design
Systematic review and meta-analysis of RCTs
Authors
Loading...
Atorvastatin lowers triglycerides in PCOS; extends RCT meta-analysis evidence for lipid improvement in this population.
Meta-Analysis
Do pharmacological interventions improve lipid profiles and reduce C-reactive protein in women with polycystic ovary syndrome?
Effect estimate: MD -0.21 mmol/L (95% CI -0.39, -0.03)
Pharmacological interventions such as atorvastatin and metformin can improve lipid profiles and reduce inflammatory markers in women with PCOS, potentially mitigating cardiovascular risk.
Abdalla et al. (2021) conducted a meta-analysis in Polycystic ovary syndrome (PCOS). Pharmacological interventions (e.g., atorvastatin, metformin, saxagliptin) vs. Placebo or other active agents was evaluated on Triglycerides (atorvastatin vs placebo) (MD -0.21 mmol/L, 95% CI -0.39, -0.03). Atorvastatin significantly reduced triglycerides (MD -0.21 mmol/L; 95% CI -0.39 to -0.03) compared to placebo in women with polycystic ovary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: